{"log_id": 1650534281677056332, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.025578, "average": 0.92501, "min": 0.359747}, "location": {"width": 1236, "top": 148, "height": 38, "left": 91}, "words": "主要疗终点是室管膜下巨细胞星形细胞缓解率,基于独立的中心放射学泮信。室管膜下巨细"}, {"probability": {"variance": 0.006398, "average": 0.952978, "min": 0.612205}, "location": {"width": 1293, "top": 203, "height": 38, "left": 34}, "words": "胞星形细胞瘤缓解的定义是体积总和与基相比缩小50,室管膜下细胞星形细胞痛非靶病灶无"}, {"probability": {"variance": 0.022356, "average": 0.912975, "min": 0.385606}, "location": {"width": 1291, "top": 258, "height": 43, "left": 34}, "words": "明确的恶化,1.0cm的新病灶,以及新出现或恶化的脑积水。室管膜下巨胞星形细胞瘤缓解率的分析"}, {"probability": {"variance": 0.020627, "average": 0.921129, "min": 0.352}, "location": {"width": 1293, "top": 313, "height": 41, "left": 32}, "words": "仅于盲态治疗期,即最后一名患者完成随机的6个封后结束。室管膜下细胞星形细胞瘤缓解率的分析"}, {"probability": {"variance": 0.017029, "average": 0.918016, "min": 0.511323}, "location": {"width": 889, "top": 368, "height": 36, "left": 32}, "words": "根据在旋机是否使用酶诱导性抗癫痛药(EAED)(是否)进行分层"}, {"probability": {"variance": 0.025237, "average": 0.899334, "min": 0.393896}, "location": {"width": 1232, "top": 422, "height": 36, "left": 89}, "words": "在入组的17名患者中,78名接受本品:39名接受安慰剂。思者的中位龄为9.5岁(范0.8~236"}, {"probability": {"variance": 0.002805, "average": 0.96739, "min": 0.762362}, "location": {"width": 1293, "top": 475, "height": 41, "left": 32}, "words": "岁:在入组69%为3至<18岁,17%为<3岁),5%为男性,3为高加索人。在基线时,18%的患者"}, {"probability": {"variance": 0.006328, "average": 0.956669, "min": 0.60069}, "location": {"width": 1289, "top": 530, "height": 41, "left": 32}, "words": "接受 EIAED。根据基线时的中心放射学评估,9%的忠者存在至少一处最长直径1.0cm时室管膜下"}, {"probability": {"variance": 0.017305, "average": 0.924618, "min": 0.408646}, "location": {"width": 1291, "top": 585, "height": 43, "left": 34}, "words": "细胞星形细胞瘤病灶,79%存在双侧室管膜下巨细胞星形细胞瘤病灶:3%存在≥2处室管膜下巨细胞"}, {"probability": {"variance": 0.015598, "average": 0.952535, "min": 0.365569}, "location": {"width": 1277, "top": 640, "height": 38, "left": 34}, "words": "形细胞瘤靶病灶,25%的病入脑室下层,存在证据表明病灶生长起过了邻近室的室管下组织"}, {"probability": {"variance": 0.007422, "average": 0.950961, "min": 0.616035}, "location": {"width": 1289, "top": 694, "height": 43, "left": 34}, "words": "7%存在脑积水的放射学证据。基线时,本品组和安慰剂组的所有室管膜下巨细胞星形细胞棉靶病灶的体"}, {"probability": {"variance": 0.017188, "average": 0.915806, "min": 0.384137}, "location": {"width": 1291, "top": 749, "height": 38, "left": 32}, "words": "积总和中位数分别为1.63cm3(范0.18~25.15cm3和1.30cm3(范围0.32~9.75cm3)。8名(7%)患者曾选"}, {"probability": {"variance": 0.020044, "average": 0.928716, "min": 0.43064}, "location": {"width": 1088, "top": 804, "height": 36, "left": 32}, "words": "行过室管膜下细胞星形细胞瘤相关的手术,中位随期为34个月(范4.6~17.2个月)"}, {"probability": {"variance": 0.016311, "average": 0.928817, "min": 0.513128}, "location": {"width": 1241, "top": 859, "height": 38, "left": 82}, "words": "在选用品治疗思者中,室管膜下巨细胞星形细胞渐缓解率高并H差异具有统计学意义。在本品组"}, {"probability": {"variance": 0.020248, "average": 0.926847, "min": 0.44533}, "location": {"width": 1291, "top": 914, "height": 38, "left": 32}, "words": "中,27名(35%)患者获得室管膜下巨纽胞星形细胞瘤缓解,而安慰剂组中未见缓解。结果见表10。在最"}, {"probability": {"variance": 0.014837, "average": 0.935946, "min": 0.477601}, "location": {"width": 1300, "top": 971, "height": 36, "left": 27}, "words": "终分析时,所有室管膜下三细胞星形胞临缓解正在进行中,缓解的中位持续时间为5.3个月(范园2.1-8.4"}, {"probability": {"variance": 0.006614, "average": 0.958172, "min": 0.675849}, "location": {"width": 848, "top": 1024, "height": 36, "left": 32}, "words": "个月)。在研究二过程中,任一治疗组中都没有患者寄手术干预治疗"}, {"probability": {"variance": 0.005378, "average": 0.9656, "min": 0.742423}, "location": {"width": 509, "top": 1078, "height": 34, "left": 29}, "words": "表10:室管膜下巨细胞星形细胞痛的缓解"}, {"probability": {"variance": 9.1e-05, "average": 0.986888, "min": 0.977353}, "location": {"width": 57, "top": 1145, "height": 32, "left": 733}, "words": "本品"}, {"probability": {"variance": 0.028178, "average": 0.833058, "min": 0.569169}, "location": {"width": 292, "top": 1145, "height": 45, "left": 941}, "words": "安慰剂户假"}, {"probability": {"variance": 7.1e-05, "average": 0.991594, "min": 0.977159}, "location": {"width": 68, "top": 1193, "height": 27, "left": 729}, "words": "N=78"}, {"probability": {"variance": 0.019954, "average": 0.848151, "min": 0.694225}, "location": {"width": 68, "top": 1193, "height": 27, "left": 953}, "words": "N=30"}, {"probability": {"variance": 6.7e-05, "average": 0.991237, "min": 0.977554}, "location": {"width": 114, "top": 1241, "height": 32, "left": 41}, "words": "最终分析"}, {"probability": {"variance": 0.010093, "average": 0.94456, "min": 0.676781}, "location": {"width": 523, "top": 1293, "height": 32, "left": 100}, "words": "室管膜下巨细胞星形细胞瘤缓解率("}, {"probability": {"variance": 0.026451, "average": 0.835481, "min": 0.672844}, "location": {"width": 27, "top": 1296, "height": 29, "left": 747}, "words": "35"}, {"probability": {"variance": 0.001316, "average": 0.946981, "min": 0.897424}, "location": {"width": 73, "top": 1346, "height": 27, "left": 105}, "words": "95%C"}, {"probability": {"variance": 0.001667, "average": 0.974336, "min": 0.893296}, "location": {"width": 80, "top": 1348, "height": 29, "left": 722}, "words": "24,46"}, {"probability": {"variance": 0.000754, "average": 0.986127, "min": 0.911119}, "location": {"width": 333, "top": 1398, "height": 34, "left": 54}, "words": "根据独立的中心放射学评估"}, {"probability": {"variance": 0.008317, "average": 0.962373, "min": 0.506616}, "location": {"width": 1241, "top": 1490, "height": 36, "left": 80}, "words": "在中位访期84个月中发现,39名随机接受安慰剂的忠者中有6名(15.4%)出现室管膜下巨细胞星形"}, {"probability": {"variance": 0.011284, "average": 0.961326, "min": 0.392946}, "location": {"width": 1067, "top": 1545, "height": 36, "left": 27}, "words": "细胞的进展,而78名随机接受本品的患者中没有发生管膜下巨细胞星形细胞进展"}, {"probability": {"variance": 0.013692, "average": 0.9394, "min": 0.460975}, "location": {"width": 1243, "top": 1602, "height": 36, "left": 77}, "words": "正究2是一项开放、单试验,评了本品治疗结节性硬化症相关的室管膜下巨细胞星形细胞瘤患者的"}, {"probability": {"variance": 0.017703, "average": 0.914265, "min": 0.480684}, "location": {"width": 1289, "top": 1659, "height": 32, "left": 25}, "words": "安全性和有效性。参加试验老需要有室管膜下巨细胞星形细胞瘤增长的一列放学证据。由独中心放射"}, {"probability": {"variance": 0.003499, "average": 0.97144, "min": 0.745798}, "location": {"width": 1277, "top": 1714, "height": 32, "left": 25}, "words": "学审,十6个月核心治疗阶段结束时评价室管膜下细胞星形维胞瘤体积改变总计28名患者使用本品治疗"}, {"probability": {"variance": 0.011204, "average": 0.947811, "min": 0.570374}, "location": {"width": 1293, "top": 1767, "height": 34, "left": 25}, "words": "中位午龄为11岁(范3-34岁)、引1%为男性、86%为高加索人。4名患者的病灶曾进行手术切除,随后在本"}, {"probability": {"variance": 0.017327, "average": 0.939884, "min": 0.357309}, "location": {"width": 1291, "top": 1821, "height": 34, "left": 22}, "words": "品治疗前出现再生长。核心治疗阶段后,患者可继续使用本品作为延长治疗阶段的一部分,室管膜下细胞"}, {"probability": {"variance": 0.008515, "average": 0.949919, "min": 0.569064}, "location": {"width": 971, "top": 1876, "height": 34, "left": 20}, "words": "星形细胞瘤体积每6个月评价一次。治疗中位时间是342个月范围4.7-47.E^月)"}, {"probability": {"variance": 0.016286, "average": 0.921765, "min": 0.544101}, "location": {"width": 1238, "top": 1931, "height": 36, "left": 80}, "words": "在6个月时,28字患者中有9名(32%,95%CT:16%~52最大管膜下细胞星形细胞痛病炉肿瘤体"}, {"probability": {"variance": 0.01572, "average": 0.937271, "min": 0.40658}, "location": {"width": 1291, "top": 1986, "height": 36, "left": 22}, "words": "积缩小≥50%,这9名患者的缓解持续时间中位数为118个月(范3.2-3.1个月)。至截止日期,9名患者中"}, {"probability": {"variance": 0.021187, "average": 0.923142, "min": 0.423346}, "location": {"width": 363, "top": 2045, "height": 32, "left": 22}, "words": "仍然7名肿瘤体积缩小≥50%"}], "language": 3}